CN117479934A - 用于治疗肾纤维化的噁二唑基二氢吡喃并[2,3-b]吡啶的HIPK2抑制剂 - Google Patents

用于治疗肾纤维化的噁二唑基二氢吡喃并[2,3-b]吡啶的HIPK2抑制剂 Download PDF

Info

Publication number
CN117479934A
CN117479934A CN202280014176.5A CN202280014176A CN117479934A CN 117479934 A CN117479934 A CN 117479934A CN 202280014176 A CN202280014176 A CN 202280014176A CN 117479934 A CN117479934 A CN 117479934A
Authority
CN
China
Prior art keywords
water
hco
mmol
condition
under
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280014176.5A
Other languages
English (en)
Chinese (zh)
Inventor
R·T·贝雷西斯
J·C·何
K·李
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icahn School of Medicine at Mount Sinai
US Department of Veterans Affairs
Original Assignee
Icahn School of Medicine at Mount Sinai
US Department of Veterans Affairs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icahn School of Medicine at Mount Sinai, US Department of Veterans Affairs filed Critical Icahn School of Medicine at Mount Sinai
Publication of CN117479934A publication Critical patent/CN117479934A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
CN202280014176.5A 2021-02-10 2022-02-09 用于治疗肾纤维化的噁二唑基二氢吡喃并[2,3-b]吡啶的HIPK2抑制剂 Pending CN117479934A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163147859P 2021-02-10 2021-02-10
US63/147,859 2021-02-10
PCT/US2022/015767 WO2022173795A1 (en) 2021-02-10 2022-02-09 OXADIAZOLYL DIHYDROPYRANO[2,3-b]PYRIDINE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS

Publications (1)

Publication Number Publication Date
CN117479934A true CN117479934A (zh) 2024-01-30

Family

ID=82837244

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280014176.5A Pending CN117479934A (zh) 2021-02-10 2022-02-09 用于治疗肾纤维化的噁二唑基二氢吡喃并[2,3-b]吡啶的HIPK2抑制剂

Country Status (9)

Country Link
US (1) US20250179084A1 (https=)
EP (1) EP4291183B1 (https=)
JP (1) JP2024506387A (https=)
KR (1) KR20230154194A (https=)
CN (1) CN117479934A (https=)
AU (1) AU2022221336A1 (https=)
CA (1) CA3210658A1 (https=)
MX (1) MX2023009323A (https=)
WO (1) WO2022173795A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240051965A1 (en) * 2022-08-05 2024-02-15 Icahn School Of Medicine At Mount Sinai Oxygen-containing heterocyclic compound and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2069335T3 (pl) * 2006-09-08 2013-05-31 Actelion Pharmaceuticals Ltd Pochodne pirydyn-3-ylu jako środki immunomodulujące
PE20091339A1 (es) * 2007-12-21 2009-09-26 Glaxo Group Ltd Derivados de oxadiazol con actividad sobre receptores s1p1
EP2210890A1 (en) * 2009-01-19 2010-07-28 Almirall, S.A. Oxadiazole derivatives as S1P1 receptor agonists
ES2907624T3 (es) * 2017-01-06 2022-04-25 Icahn School Med Mount Sinai Inhibidores de oxadiazol de HIPK2 para el tratamiento de la fibrosis renal
JP7252908B2 (ja) * 2017-06-14 2023-04-05 トレベナ・インコーポレイテッド Ｓ１ｐ１活性を調節するための化合物およびその使用法

Also Published As

Publication number Publication date
MX2023009323A (es) 2023-12-14
WO2022173795A1 (en) 2022-08-18
US20250179084A1 (en) 2025-06-05
JP2024506387A (ja) 2024-02-13
EP4291183A1 (en) 2023-12-20
AU2022221336A1 (en) 2023-08-24
EP4291183B1 (en) 2026-04-08
KR20230154194A (ko) 2023-11-07
EP4291183A4 (en) 2025-01-08
CA3210658A1 (en) 2022-08-18

Similar Documents

Publication Publication Date Title
WO2022258040A1 (zh) 用于tead抑制剂的杂环化合物
CN112552295A (zh) Kras突变蛋白抑制剂
CN111868055B (zh) Trpc6的抑制剂
WO2018157856A1 (zh) 酰胺类衍生物抑制剂及其制备方法和应用
WO2020063792A1 (zh) 吲哚类大环衍生物、其制备方法及其在医药上的应用
JP7175481B2 (ja) ベンゾイソオキサゾール化合物
WO2022100623A1 (zh) 氮取代杂环噻吩类化合物及其用途
WO2021244634A1 (zh) 咪唑并吡啶类化合物及其用途
TWI891227B (zh) 用於治療與apj受體活性相關的病狀的化合物及組成物
JP2024505732A (ja) ピリドピリミジノン系誘導体及びその製造方法と使用
WO2022105852A1 (zh) 三嗪二酮类衍生物、其制备方法及其在医药上的应用
WO2025051180A1 (zh) 内酰胺类衍生物及其应用
CN112513041B (zh) 三环化合物
CN117479934A (zh) 用于治疗肾纤维化的噁二唑基二氢吡喃并[2,3-b]吡啶的HIPK2抑制剂
WO2021129841A1 (zh) 用作ret激酶抑制剂的化合物及其应用
WO2025113627A1 (zh) 含杂环的tead抑制剂
CN119143734A (zh) 作为at2r拮抗剂的杂环化合物及其用途
WO2025051267A1 (zh) 一种lpar1拮抗剂及其用途
WO2023116877A1 (zh) 作为tead抑制剂的杂环化合物
CN107428682B (zh) 酰胺类衍生物、其制备方法及其在医药上的用途
WO2023116763A1 (zh) 一种哒嗪类化合物、其药物组合物及应用
WO2023125486A1 (zh) 生长抑素受体5拮抗剂及其药物组合物及用途
CN114591317A (zh) P2x3抑制剂及其用途
WO2022166923A1 (zh) 苯基二氢嘧啶类化合物及其应用
WO2021004487A1 (zh) 噻唑烷二酮衍生物以及包含其的药物组合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination